257 - Cracking the Code of Resistance: A Deep Dive Into Metallo-Beta-Lactamase From Bench to Bedside

Wednesday, October 22, 2025

3:15 PM - 4:30 PM US ET

Location: Thomas B. Murphy Ballroom 4

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Yohei Doi, MD, PHD (he/him/his)

Professor of Medicine
Division of Infectious Diseases
University of Pittsburgh
Toyoake, Aichi, Japan
Amy Mathers, MD, D(ABMM) (she/her/hers)

Professor of Medicine and Pathology
University of Virginia
Charlottesville, VA, United States

Faculty(s)

Emily Heil, PharmD, MS

Professor
Infectious Diseases
University of Maryland School of Pharmacy
Baltimore, MD, United States
MM

Maria Mojica, PhD (she/her/hers)

Senior Instructor
Case Western Reserve University
Cleveland, OH, United States
AV

Alejandro Vila, PhD (he/him/his)

Professor
Instituto de Biología Molecular y Celular de Rosario (IBR)
Rosario, Santa Fe, Argentina

Disclosure(s):

Yohei Doi, MD, PHD: GSK: Advisor/Consultant; Meiji Seika Pharma: Advisor/Consultant; Shionogi: Advisor/Consultant, Honoraria

Amy Mathers, MD, D(ABMM): Cephied: Advisor/Consultant; DayZero Diagnostics: Advisor/Consultant

Emily L. Heil, PharmD, MS: Wolters-Kluwer: Advisor/Consultant

Maria F. Mojica, PhD: No financial relationships to disclose.

Alejandro J. Vila, PhD: SHIONOGI and CO., LTD.: Grant/Research Support

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the biochemical structure, function, and classification of metallo-beta-lactamases (MBLs) and their role in antibiotic resistance;
analyze recent research findings on the genetic and molecular mechanisms driving MBL-mediated resistance in clinical pathogens;
evaluate current and emerging therapeutic strategies, including novel inhibitors and alternative treatment approaches targeting MBL-producing bacteria;
apply knowledge of MBL resistance patterns to optimize antimicrobial stewardship and infection control practices in clinical settings.

Presentations:

3:15 PM - 3:40 PM US ET

Unmasking Resistance: Epidemiology and Diversity of MBLs
Speaker: Maria F. Mojica, PhD (she/her/hers) – Case Western Reserve University
3:40 PM - 4:05 PM US ET

Targeting the Untargetable: Strategies tor Designing New Drugs Against MBLs
Speaker: Alejandro J. Vila, PhD (he/him/his) – Instituto de Biología Molecular y Celular de Rosario (IBR)
4:05 PM - 4:30 PM US ET

Advances in Treating MBL-Producing Gram-Negative Infections
Speaker: Emily L. Heil, PharmD, MS – University of Maryland School of Pharmacy